Is PrEP -- the HIV Prevention Pill -- Right For Your Patient? | |
 | This assessment tool will help you determine whether HIV pre-exposure prophylaxis (PrEP) is an optimal fit for your patients or clients. |
This Week in HIV Research: Non-AIDS Cancers More Common as People With HIV Age | |
A study finds that as people living with HIV continue to age, the prevalence of non-AIDS-defining cancers will go up. |  |
Low Vitamin D Decreases Impact of Statins in People With HIV | |
 | Having low vitamin D levels was associated with diminished impact of statins on cholesterol for participants in the SATURN-HIV study. |
Getting Real on Smoking and HIV Prevention | |
What works and doesn't work for helping people to quit smoking? |  |
An ongoing series to help providers set the foundations of a patient's care.
What's New or Notable in HIV Treatment and Prevention Adherence?
Progress and Gaps in Scaling Up Universal HIV Treatment in Africa
Starting HIV Treatment Soon After Diagnosis Trims Time to Viral Suppression
What's the Next Game-Changer in HIV Treatment?
The field of hepatitis C disease management is in the midst of dramatic change. This series provides overviews, research updates, and more.
Addressing Hepatitis C Treatment Barriers Among HCV/HIV-Coinfected Patients
What Are the Hepatitis C Genotypes?
Real-World Hepatitis C Cure Rates Higher With 2 Direct Acting Agents
Hepatitis C Resources, Services and Information
British Columbia Researchers Study HIV Treatment Interruptions and Their Consequences
Darunavir/Cobicistat/FTC/TAF: 24-Week Interim Results From Phase 3 Switch Study
Phase 3 Results With Bictegravir -- A New Integrase Inhibitor Combined With FTC/TAF
Isentress HD in Clinical Trials
Maintaining HIV Service Organizations Effectiveness in the New Prevention and Treatment Landscape
Mystifying Cochrane Library Review on HCV Therapy Elicits Strong Response from IDSA
Know Your Drugs and Classes of HCV Treatment
Isentress HD: A New Once-Daily Formulation of Raltegravir Approved in Canada
Declining Funding and Shrinking Donor Base Imperils Continued Success of HIV Prevention
FDA Approves Vosevi for Hepatitis C
Who's Most at Risk of Getting Kaposi Sarcoma? New Research Gives Insights
Depression and Anxiety Not Barriers to HCV Treatment Success
Notice to readers: TheBodyPRO.com's privacy policy was updated on Sept. 20, 2016.
© 2017 Remedy Health Media, LLC. All Rights Reserved
TheBodyPRO.com: About TheBodyPRO.com | Contact TheBodyPRO.com | Content Policy | Advertise With Us
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
TheBodyPRO.com is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
